Evaluating WATCHMAN Device Versus Standard Care to Prevent Stroke in High-Risk Atrial Fibrillation Patients
Led by Hamilton Health Sciences Corporation · Updated on 2026-09-18
4000
Participants Needed
150
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether catheter-based endovascular left atrial appendage occlusion can reduce the risk of ischemic stroke or systemic embolism in people with atrial fibrillation who remain at high stroke risk despite ongoing oral anticoagulation treatment. This multicenter, open-label, randomized controlled trial with blinded assessment aims to clarify the benefit of this intervention for stroke prevention in this population.
Participants are randomly assigned to receive either the WATCHMAN device for left atrial appendage occlusion or standard medical care without this procedure. The WATCHMAN device is placed via a catheter to close off the left atrial appendage. Participants continue their oral anticoagulation as prescribed. The study expects an average follow-up of about 4 years, with the primary analysis conducted after 265 stroke or embolism events have occurred.
During the study, participants undergo regular monitoring and assessments to track the occurrence of ischemic stroke, systemic embolism, and other cardiovascular events. Cognitive function is also evaluated using the Montreal Cognitive Assessment. Safety and mortality outcomes will be recorded throughout the trial duration. Participants are followed for the full study period estimated at around 4 years to gather comprehensive data on the interventions effects.
CONDITIONS
Brief Title
The Fourth Left Atrial Appendage Occlusion Study
Research Team
P
Program Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
WATCHMAN device
Standard anticoagulation
Standard oral anticoagulation (DOACs)
What it is
Percutaneous left atrial appendage occlusion using the WATCHMAN device
Continuation of oral anticoagulant therapy (Vitamin K antagonist or factor Xa inhibitor)
Ongoing use of direct oral anticoagulants as the current standard preventive strategy
Control arm continuing on anticoagulants rather than procedural intervention
Reflects current recommended therapy used in typical clinical care
Primary use
Mechanical closure of left atrial appendage to prevent stroke
Stroke prevention using oral anticoagulation
Stroke prevention with DOACs as recommended current standard
How it is given or performed
Procedure—percutaneous catheter delivery of device into left atrial appendage
Oral intake of Vitamin K antagonist or factor Xa inhibitor drugs
Oral use of DOAC medications as prescribed in routine management
Evidence status
Evidence is being generated by this trial to assess stroke prevention benefit
Known efficacy in reducing ischemic stroke in AF populations
Strong evidence supports DOACs as effective prevention
Important risks
Procedural complications such as pericardial effusion, device‑related thrombus, incomplete seal
Bleeding risk and adverse effects from long‑term anticoagulants
Bleeding and adherence challenges associated with long‑term DOAC use
Important limitations
Long‑term efficacy and safety results pending; procedural risks under study
Effectiveness depends on adherence and tolerability of anticoagulants
Some patients have contraindications or bleeding risk limiting DOAC use
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Adults aged 18 years or older
Diagnosis of persistent or permanent atrial fibrillation, or paroxysmal atrial fibrillation with prior ischemic stroke or systemic embolism
High stroke risk with a CHA2DS2-VASc score of 4 or greater
Receiving oral anticoagulants (Vitamin K antagonist or factor Xa inhibitor) for at least 90 days before enrollment
No plans to stop oral anticoagulants during the study
You will not qualify if you...
Under 18 years of age
Current blood clot in the left atrial appendage
Previous left atrial appendage occlusion or removal
Previous percutaneous closure of atrial septal defect or patent foramen ovale
Previous atrial fibrillation ablation without recurrent qualifying atrial fibrillation at least 30 days after procedure
Planned atrial fibrillation ablation within 90 days of enrollment
Treatment with direct thrombin inhibitors
Women of childbearing potential not agreeing to effective birth control during the study
Life expectancy less than 2 years
Unable or unwilling to provide informed consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 4 years or until study completion based on events
Participants receive either the WATCHMAN device through a catheter procedure or continue with standard medical care without the device.
Regular follow-up visits as scheduled
Follow-up
Duration - Up to 4 years or until study completion based on events
Participants are monitored for stroke, systemic embolism, cognitive function, and survival outcomes during the study period.
Periodic assessments throughout the study
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Using 320-Detector CT to Measure Heart Tissue Fibrosis in Adults with Atrial Fibrillation
Before Catheter Ablation Treatment
Comparing Simple and Standard Imaging Methods for Selecting Stroke Patients for Endovascular Treatment in the NO-SELECT Trial
Long-Term Safety and Effectiveness Evaluation of the VARIPULSE Catheter System in Symptomatic Paroxysmal Atrial Fibrillation Management
Evaluating Safety and Effectiveness of Dual Energy THERMOCOOL SMARTTOUCH SF Catheter With TRUPULSE Generator in Persistent Atrial Fibrillation
Evaluating Varipulse Catheter Ablation Using Different Anesthesia Types in Adults With Paroxysmal Atrial Fibrillation
Safety and Effectiveness of the VARIPULSE Catheter System for Treating Persistent Atrial Fibrillation
Using Pulmonary Vein, Superior Vena Cava, and Posterior Wall Isolation
Including Left Atrial Appendage Occlusion Procedures
Randomized Trial Comparing VARIPULSE and FARAWAVE Pulsed Field Ablation Catheters in Treating Persistent Atrial Fibrillation
Randomized, Double-Blind Study Evaluating Oral PKN605 Compared to Placebo in Adults with Atrial Fibrillation to Assess Efficacy, Safety, and Pharmacokinetics
Evaluating BAY 3670549 Compared to Placebo for Treating Atrial Fibrillation with Electrical Cardioversion in Adults
Village Doctor-led Telehealth Care vs Usual Care for Older Adults with Atrial Fibrillation and Heart Failure in Rural China The MIRACLE AF-HF Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Clinical Features, Management, and Recurrence of Acute Ischemic Stroke Occurring in Patients on Oral Anticoagulant Treatment for Nonvalvular Atrial Fibrillation: A Real-World Retrospective Study.